{"title":"Neuroprotective Effect of Morinda citrifolia on Behavioural and Biochemical Deficits in PTZ-induced Kindled Mice.","authors":"Moazzam Ali, Prabhat Singh, Lubhan Singh, Rupesh Kumar Pandey, Priyadarshini Soni, Akansha Singh","doi":"10.2174/1871526523666230605160222","DOIUrl":"https://doi.org/10.2174/1871526523666230605160222","url":null,"abstract":"<p><strong>Introduction: </strong>Epilepsy is a group of chronic neurological disorders characterized by seizures. Kindling, a chronic epileptic mouse model, was used to explore the epileptogenic mechanism and seek new anti-epileptics. In kindling, sub-convulsive (chemical/ electrical) stimuli were delivered repeatedly and erratically, eventually causing massive convulsions. Moreover, Morinda citrifolia (Noni) extracts are used as a remedy in ayurvedic preparations for many ailments. Noni has recently been shown to protect mice from amyloid beta-induced memory loss.</p><p><strong>Objective: </strong>This study was used to investigate the neuroprotective potential of Morinda citrifolia in mice over pentylenetetrazol (PTZ)-induced kindling seizure.</p><p><strong>Methods: </strong>Kindling was provoked by subsequent (one-day-gap) injections of PTZ (subconvulsive; 35 mg/kg; s.c.) for 29 days in mice. Following PTZ injection, convulsive behaviours were noted for 30 minutes. Open-field-test (locomotor activity), forced swimming test (depressive behaviors), elevated plus-maze, and passive avoidance tests were employed to evaluate cognition. Brain homogenate was used to estimate oxidative stress (glutathione, superoxide-dismutase, lipid-peroxidation) and acetylcholinesterase activity.</p><p><strong>Results: </strong>PTZ-provoked kindled mice displayed depressive behaviors, impaired locomotion, cognitive dysfunctions and various biochemical changes. However, treatment with Morinda citrifolia extract (500 and 1000 mg/kg, p.o) and valproic acid (200 mg/kg, p.o) before 60 min of each PTZ injection diminished kindling scores and restored behavioural, and biochemical changes.</p><p><strong>Conclusion: </strong>Our findings suggest Morinda citrifolia offered neuroprotective effects against PTZinduced kindling seizures in mice, which were established by behavioural and biochemical paradigms.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9586694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Effectiveness of Face Masks in Preventing COVID-19 Transmission: A Systematic Review.","authors":"SeyedAhmad SeyedAlinaghi, Amirali Karimi, Amir Masoud Afsahi, Pegah Mirzapour, Sanaz Varshochi, Hengameh Mojdeganlou, Paniz Mojdeganlou, Armin Razi, Sanam Alilou, Mohsen Dashti, Afsaneh Ghasemzadeh, Solmaz Saeidi, Esmaeil Mehraeen, Omid Dadras","doi":"10.2174/1871526523666230601090905","DOIUrl":"https://doi.org/10.2174/1871526523666230601090905","url":null,"abstract":"<p><strong>Introduction: </strong>Since the beginning of the COVID-19 pandemic, face masks have been among the cornerstones of COVID-19 prevention. Therefore, evaluating their preventive effects against COVID-19 is crucial. This review aimed to systematically search for the systematic review articles that explored the role of various types of face masks in preventing COVID-19.</p><p><strong>Methods: </strong>We browsed the keywords of this study in the online databases of Scopus, Web of Science, PubMed, and Cochrane on 10th January 2023 and retrieved all the relevant systematic review articles. The records were downloaded into an Endnote file, and the duplicates were removed. A two-step screening process consisting of title/abstract and full-text screenings was conducted to select the most relevant articles. To ensure the validity and reliability of the results, this study adhered to the PRISMA protocol.</p><p><strong>Results: </strong>A total of 28 systematic reviews were included in this review. Most studies found that face masks are beneficial against viral respiratory infections, such as COVID-19. Different types of masks were evaluated in included studies. It appeared that mask efficacy depends on the material, layers, fitting on the face and user compliance. N 95 respirator had maximum efficacy, especially when used continuously.</p><p><strong>Conclusion: </strong>Face masks have a beneficial effect against COVID-19. Home masks are less protective than surgical masks or N95 personal breathing masks. Besides, the use of masks may elicit a false sense of security in people, which may lead to poor hand hygiene and violation of social distancing. Therefore, the necessary training should be provided to the public to increase awareness and encourage the right practice of using the mask, emphasizing the preventive effects of washing hands, social distancing, and using a face mask against COVID-19.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9554536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"WITHDRAWN: Th17 Overexpression in Severe COVID-19: A Prospective Observational Study","authors":"Ankesh Gupta, Arvind Kumar, Rakesh Kumar Deepak, Umang Arora, Aayush Agrawal, Manish Soneja, Prerna Garg, Sanchit Kumar, Praveen Kumar, Uma Kanga, Ganesh Kumar V, Kapil Dev Soni, Naveet Wig","doi":"10.2174/1871526523666230531115839","DOIUrl":"10.2174/1871526523666230531115839","url":null,"abstract":"<p><p>Since the authors are not responding to the editor’s requests to fulfil the editorial requirement, therefore, the article has been withdrawn from the journal \"Infectious Disorders - Drug Targets\"</p><p><p>Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.</p><p><strong>Bentham science disclaimer: </strong>It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submit-ting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9607345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Does Widespread Use of Hydroxychloroquine Reduce the Transmissibility of SARS-CoV-2 / COVID-19? An Ecological Correlational Study.","authors":"Fabricio Souza Neves","doi":"10.2174/1871526523666230522114836","DOIUrl":"10.2174/1871526523666230522114836","url":null,"abstract":"<p><strong>Background: </strong>At the beginning of the coronavirus disease (COVID-19) pandemic, hydroxychloroquine (HCQ) was widely used as a possible antiviral agent. Current knowledge indicates that HCQ has little or no effect on individual clinical outcomes of COVID-19, but populational effects on disease transmissibility are still unknown.</p><p><strong>Objective: </strong>This study investigates the hypothesis that massive HCQ consumption by a population may contribute to reducing the transmissibility of SARS-CoV-2 and COVID-19 spread by reducing the viral load of infected individuals.</p><p><strong>Methods: </strong>Public database of seven states from Brazil in 2020 were assessed, before the start of COVID-19 vaccination. The daily values of the COVID-19 effective reproduction number (Rt) were obtained. Associations between Rt values and the proposed predictor variables (prevalence of COVID-19 as a marker of collective immunity; social isolation indices; consumption of HCQ) were tested using multiple linear regression analysis.</p><p><strong>Results: </strong>In all seven states, consumption of HCQ was a significant negative predictor of Rt (β ranged from -0.295 to -0.502, p = 0.001). Furthermore, the mean derivative of Rt during the declining period of the COVID-19 incidence (the mean rate of variation) was also significantly negatively related to the mean HCQ consumption in that period (R2 = 0.895; β = -0.783; p = 0.011), meaning that the higher the HCQ consumption, the faster the decline of COVID-19 Rt. It suggests a dose-response phenomenon and a causal relationship in this association.</p><p><strong>Conclusion: </strong>The results of this study are compatible with the hypothesis that HCQ has small but significant in vivo antiviral effects that are able to reduce SARS-CoV-2 transmissibility at the populational level.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9876165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Praveen Kumar Uppala, Anjaly Mary Varghese, Sree Sudha Ty, Hemasri Velmurugan, Pugazhenthan Thangaraju, K S B S Krishna Sasanka
{"title":"Capecitabine and Hand-foot Syndrome: A Case Report.","authors":"Praveen Kumar Uppala, Anjaly Mary Varghese, Sree Sudha Ty, Hemasri Velmurugan, Pugazhenthan Thangaraju, K S B S Krishna Sasanka","doi":"10.2174/1871526522666220614162117","DOIUrl":"https://doi.org/10.2174/1871526522666220614162117","url":null,"abstract":"<p><p>Capecitabine, a prodrug of 5-fluorouracil, is an FDA-approved drug for adjuvant treatment of colon, metastatic colorectal, and breast cancer. A variety of mucocutaneous adverse effects has been recognized with capecitabine. The pathogenesis of such manifestations still remains an enigma though various theories have been proposed. Here, we report two such cases. A 59-year-old female with carcinoma of the sigmoid colon on palliative therapy developed localized cutaneous hyperpigmentation of the palms and soles secondary to capecitabine in her 2nd cycle. Another case was of a 42-year-old female with stomach adenocarcinoma, who developed similar adverse effects after administration of capecitabine in her 4th cycle. Since these drugs have been widely used in recent years due to their relative ease in administration, the relative unawareness of Hand-foot syndrome (HFS) caused due to this drug makes it a prudent topic to be reported.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10670760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A New Year, Newfangled COVID-19 Variant B.1.640.2 (IHU): What We Know So Far?","authors":"Suman Kumar Ray, Sukhes Mukherjee","doi":"10.2174/1871526522666220831101802","DOIUrl":"https://doi.org/10.2174/1871526522666220831101802","url":null,"abstract":"<p><p>A new COVID-19 variant that no one currently wants has emerged with the start of the new year. Omicron, which was first discovered in November of last year, was only just beginning to be understood when another strain uncovered in France made headlines. On January 4, 2022, news of the variant exploded on social media, but cases of what is now known as variant B.1.640.2 (IHU) were initially discovered about two months prior. Evidence is still being gathered, but internet misinformation regarding the latest coronavirus variety is already rampant, as it was with Omicron. The majority of existing vaccines target SARS-spike CoV-2's protein, which the virus utilizes to enter and infect cells. Epidemiologists and virologists worldwide are concerned about the virus' spike protein, which plays a key role in how your body identifies and reacts to the virus. Spike proteins are produced, recognized, and defended against by our immune system. Your body and the vaccines you have had injected into your system have a far harder time fighting the virus when the amino acids in a protein are altered or removed.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9771907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Determinants of Treatment Delay and Quality of Life among the Newly Diagnosed Pulmonary Tuberculosis Patients in Northeastern Thailand: A Cross-Sectional Study.","authors":"Phiman Thirarattanasunthon, Paleeratana Wongrith, Omid Dadras, Surasak Kabmuangpak","doi":"10.2174/1871526522666220818142651","DOIUrl":"https://doi.org/10.2174/1871526522666220818142651","url":null,"abstract":"<p><strong>Background/objective: </strong>Delays in diagnosing pulmonary tuberculosis (PTB) are linked to financial difficulties, employment limits, dependency, and symptomatic treatment, all of which have an impact on the patient's quality of life. Patients' psychological, economic, and social well-being are also harmed by delayed therapy. The goal of this research was to evaluate sociodemographic characteristics and quality of life in new pulmonary TB patients and determine the associated factors with delayed TB diagnosis.</p><p><strong>Methods: </strong>This was a cross-sectional study conducted in the Choke Chai Community Hospital, in Northeastern Thailand between 2016 and 2018. The information related to the patient's medical history and laboratory tests were gathered from 332 newly diagnosed tuberculosis patients at the hospital's tuberculosis clinic; of those 15 died and were excluded from the final analysis. Data were analyzed using SPSS version 17.0.</p><p><strong>Results: </strong>The cases included new cases (94%) and those returning to receive treatment after discontinuation of treatment, relapse, or recurrence of the disease (6%). The sample consisted of 68.7% males and 31.3% females. The average age was 52.7 years (S.D = 15.64). The majority of patients were married (60.5%), employed (68.6%), received a low income (66.6%), had a history of chronic diseases (73%), drank alcohol (31.7%), and smoked (85.7%). Approximately half of PTB experienced treatment delay and had a low quality of life (QoL) (46.6%). The treatment delay was associated with age > 50 years (p <0.05), low self-care (p <0.05), long distance to facility (p <0.05), unavailable caretaker to treat (p <0.05), no caregiver in family (p <0.05), high expenses (p <0.01), and lack of information (p <0.001).</p><p><strong>Conclusion: </strong>It appeared that the patients' health-related quality of life could be deteriorated as a result of pulmonary tuberculosis. Treatment delays can be significantly reduced by changing the understanding of family caregivers, increasing awareness, providing adequate support for patients, and guaranteeing early diagnosis and treatment by implementing an efficient surveillance system.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9830702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Applications of Chitosan Derivatives as Adjuvant for Nanoparticles Based Vaccines.","authors":"R Ram Narayanan, Saba Maanvizhi","doi":"10.2174/1871526522666220922102621","DOIUrl":"https://doi.org/10.2174/1871526522666220922102621","url":null,"abstract":"<p><p>This review focuses on the applications of chitosan derivatives towards vaccine delivery for their role as adjuvants. Adjuvants have been used as one of the key components in modern-day vaccines to enhance the immune response or as a drug delivery carrier. Generally, vaccines are administered to protect the host against harmful disease-causing infectious pathogens. The area of vaccine delivery is reaching new heights day by day with the evolution of the strategies and tools used for vaccine development. Currently, the vaccines have created a great impact by saving the lives of many human beings. A narrative review of all the relevant papers were conducted across the databases of PubMed and ScienceDirect. Based on the various studies performed in various animal models, the chitosan nanoparticle (CNP) was reported to be a safe and effective adjuvant candidate for a wide range of prophylactic and therapeutic vaccines that require a balanced and potent stimulation of both the cellular and humoral responses, due to its natural origin and good biocompatibility, as well as its lack of lethal toxicity to humans and animals. There was a tremendous shift in the paradigm of vaccine drug delivery from the use of conventional to novel adjuvants. For the development of a promising vaccine delivery system, adjuvant plays an irreplaceable role, but the adjuvants have not been utilized to their full potential because of the limited number of approved adjuvants. Hence the search for novel adjuvants is highly increased. In the list of versatile adjuvants, chitosan derivatives occupy an important place because of their huge benefits. The chitosan derivatives are obtained by the chemical modification of chitosan. The studies performed on various animal models validate the potential use of chitosan dervatives as adjuvants for vaccine delivery.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9830710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Post-Exposure Prophylaxis for COVID-19: A Systematic Review.","authors":"SeyedAhmad SeyedAlinaghi, Amirali Karimi, Zahra Pashaei, Parnian Shobeiri, Nazanin Janfaza, Farzane Behnezhad, Afsaneh Ghasemzadeh, Alireza Barzegary, Ghazal Arjmand, Alireza Noroozi, Alireza Shojaei, Ava Amiri, Farzin Vahedi, Mehrdad Mahalleh, Ahmadreza Shamsabadi, Mohsen Dashti, Amir Masoud Afsahi, Esmaeil Mehraeen, Omid Dadras","doi":"10.2174/1871526523666230413082721","DOIUrl":"https://doi.org/10.2174/1871526523666230413082721","url":null,"abstract":"<p><strong>Introduction: </strong>SARS-CoV-2 cause pneumonia can spread across the lung and lead to acute respiratory distress syndrome (ARDS) in severe cases. Post-exposure prophylaxis has shown great potential to prevent the transmission of some viral infections; however, such results for COVID-19 are still inconclusive.</p><p><strong>Methods: </strong>Therefore, the aim of this study was to systematically review the resources that utilized postexposure prophylaxis (PEP) for COVID-19 and the possible clinical benefits of such drugs. An organized search of relevant literature was done using the keywords and search queries on public databases of Cochrane, PubMed, Web of Science and Scopus from December 2019 to August 23, 2021. Original resources that had the inclusion criteria were included after two-phase title/abstract and full-text screenings. This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta- Analysis (PRISMA) statement.</p><p><strong>Results: </strong>Out of 841 retrieved records 17 resources were appropriate to include in the systematic review. Hydroxychloroquine with a daily dose of 400-800 mg and a duration of 5-14 days was the most frequently used agent for PEP. Chloroquine was recommended to use to control treatment in patients with mild to severe COVID-19 pneumonia. Other agents like Lopinavir-ritonavir (LPV/r), angiotensinconverting enzyme inhibitors (ACEIs), Angiotensin receptor blockers (ARBs), Vitamin D, arbidol, thymosin drugs, and Xin guan no.1 (XG.1, a Chinese formula medicine) have also been applied in some studies.</p><p><strong>Conclusion: </strong>Current evidence demonstrated no established clinical benefits of any drug as PEP in individuals with COVID-19. However, scarce indication occurs for the beneficial effects of some agents, but more studies are needed to explore such effects.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9844676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Biofilm Formation Status in ESBL-Producing Bacteria Recovered from Clinical Specimens of Patients: A Systematic Review and Meta-Analysis.","authors":"Masoud Keikha, Mohsen Karbalaei","doi":"10.2174/1871526522666220920141631","DOIUrl":"https://doi.org/10.2174/1871526522666220920141631","url":null,"abstract":"<p><strong>Background: </strong>Recently, the emergence and spread of extended-spectrum beta-lactamase (ESBL) bacteria have become a global health concern. In addition, the ability to form biofilm due to less impermeability to antibiotics and the horizontal transformation (conjugation) of genes involved in antibiotic resistance have exacerbated the concerns. With a comprehensive meta-analysis, this study evaluated the potential relationship between ESBL and biofilm formation.</p><p><strong>Methods: </strong>A literature search was performed using global databases, such as PubMed and Scopus, up to November 2021. We retrieved all relevant documents and selected eligible articles based on inclusion criteria. Finally, the potential association between the biofilm formation capacity and resistance of ESBL-producing bacteria was measured with an odds ratio and a 95% confidence interval.</p><p><strong>Results: </strong>In the present study, 17 articles, including 2,069 Gram-negative isolates, were considered as eligible. The prevalence of biofilm formation in all clinical isolates of ESBL and non-ESBL pathogens was 72.4% (95% CI: 60.7-81.6) and 40.5% (95% CI: 30.2-51.8), respectively. Our results showed a positive relationship between the ability for biofilm formation and conferring antibiotic resistance in ESBL-producing bacteria (OR: 3.35; 95% CI: 1.67-6.74; p-value: 0.001).</p><p><strong>Conclusion: </strong>In general, we showed the rate of biofilm formation to be significantly higher in ESBLproducing strains. Given the current results, the updated therapeutic guidelines should consider the role of biofilm production for optimal therapy, treatment course, and clinical outcomes rather than the recommendation of antimicrobial agents by focusing on the results of the antibiotic susceptibility test.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10133356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}